Novavax reported $203.41M in Net Income for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Agenus AGEN:US $ -46.43M 1.89M
AstraZeneca AZN:LN 360M 26M
Astrazeneca AZN:US $ 360M 26M
Biocryst Pharmaceuticals BCRX:US $ -58.86M 15.34M
Dynavax Technologies DVAX:US $ 128.76M 95.9M
Genocea Biosciences GNCA:US $ -15.98M 2.7M
Geron GERN:US $ -28.12M 1.98M
GlaxoSmithKline GSK:LN 838M 964M
Mannkind MNKD:US $ -29.02M 3.02M
Merk MRK:US $ 3944M 366M
Minerva Neurosciences NERV:US $ -8.72M 1.05M
Moderna Inc MRNA:US 2.2B 1.46B
Novartis NVS:US $ 1694M 528M
Pain Therapeutics PTIE:US $ -19.33M 1.8M
Peregrine Pharmaceuticals PPHM:US $ 115.6M 113.35M
Pfizer PFE:US $ 9905M 2042M
Sarepta Therapeutics SRPT:US $ -231.48M 126.46M
Tg Therapeutics TGTX:US $ -40.51M 28.5M